Amryt Pharma plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Amryt Pharma plc, a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments for rare and orphan diseases, offers a portfolio of specialized therapies including metreleptin (Myalept/Myalepta) for generalized lipodystrophy as an adjunct to diet; lomitapide (Juxtapid/Lojuxta) for homozygous familial hypercholesterolemia; and other assets such as Mycapssa for acromegaly treatment alongside a pipeline targeting neuroendocrine tumors and dystrophic epidermolysis bullosa. The company, founded in 2015 and headquartered in Dublin, Ireland, maintains operations across North America, Europe and select international markets through offices in the United States, United Kingdom, Ireland and Germany. In April 2023, Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A., an Italy-based research-focused biopharmaceutical group specializing in rare diseases, in a transaction valued at up to $1.48 billion that integrates Amryt's products and pipeline into Chiesi's global rare diseases unit to expand patient access and accelerate development efforts.
Poolbeg Pharma beefs up leadership; brings key players from succesful Amryt Pharma team
Amryt Pharma: Final Chance To Pick Up An Attractive CVR
Why Shares of Amryt Pharma Jumped This Week
Acquisition Of Amryt Pharma: How To Profit From Orphan Drugs Developers
New Strong Sell Stocks for December 7th
New Strong Sell Stocks for November 17th
New Strong Sell Stocks for November 16th
New Strong Sell Stocks for November 10th
Amryt Pharma PLC (AMYT) Q3 2022 Earnings Call Transcript
Amryt to Report Q3 2022 Results on November 3, 2022
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022
Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates
Amryt to Report Q2 2022 Results on August 4, 2022
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
Amryt Pharma PLC Sponsored ADR (AMYT) Surges 7.5%: Is This an Indication of Further Gains?
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022
Amryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call Transcript
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q1 Loss, Tops Revenue Estimates
Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease